Characterization of rabies pDNA nanoparticulate vaccine in poloxamer 407 gel
Characterization of rabies pDNA nanoparticulate vaccine in poloxamer 407 gel
复制标题
DOI:
10.1016/j.ijpharm.2018.05.018
复制
发表时间:
2018-07-10
影响因子:
5.8
通讯作者:
D'Souza, Martin J.
中科院分区:
文献类型:
--
作者:
Bansal, Amit;Wu, Xianfu;D'Souza, Martin J.
Plasmid DNA (pDNA) vaccines have the potential for protection against a wide range of diseases including rabies but are rapid in degradation and poor in uptake by antigen-presenting cells. To overcome the limitations, we fabricated a pDNA nanoparticulate vaccine. The negatively charged pDNA was adsorbed onto the surface of cationic PLGA (poly (D, L-lactide-co-glycolide))-chitosan nanoparticles and were used as a delivery vehicle. To create a hydrogel for sustainable vaccine release, we dispersed the pDNA nanoparticles in poloxamer 407 gel which is liquid at 4 degrees C and turns into soft gels at 37 degrees C, providing ease of administration and preventing burst release of pDNA. Complete immobilization of pDNA to cationic nanoparticles was achieved at a pDNA to nanoparticles ratio (P/N) of 1/50. Cellular uptake of nanoparticles was both time and concentration dependent and followed a saturation kinetics with V-max of 11.389 mu g/mL h and K-m of 139.48 mu g/mL. The in vitro release studies showed the nanoparticulate vaccine has a sustained release for up to 24 days. In summary, pDNA PLGA-chitosan nanoparticles were non-cytotoxic, their buffering capacity and cell uptake were enhanced, and sustained the release of pDNA. We expect our pDNA vaccine's potency will be greatly improved in the animal studies.